Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × lorvotuzumab mertansine × Clear all
NCT01237678 2018-01-18

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Terminated
181 enrolled 17 charts
Thoracic

Small Cell Lung Carcinoma

NCT00065429 2012-07-18

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Completed
64 enrolled 13 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡